NK Cell-Based Glioblastoma Immunotherapy
Glioblastoma (GB) is the most aggressive and most common malignant primary brain tumor diagnosed in adults. GB shows a poor prognosis and, unfortunately, current therapies are unable to improve its clinical outcome, imposing the need for innovative therapeutic approaches. The main reason for the poo...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2018-12-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/10/12/522 |
| _version_ | 1797709780061519872 |
|---|---|
| author | Irene Golán Laura Rodríguez de la Fuente Jose A. Costoya |
| author_facet | Irene Golán Laura Rodríguez de la Fuente Jose A. Costoya |
| author_sort | Irene Golán |
| collection | DOAJ |
| description | Glioblastoma (GB) is the most aggressive and most common malignant primary brain tumor diagnosed in adults. GB shows a poor prognosis and, unfortunately, current therapies are unable to improve its clinical outcome, imposing the need for innovative therapeutic approaches. The main reason for the poor prognosis is the great cell heterogeneity of the tumor mass and its high capacity for invading healthy tissues. Moreover, the glioblastoma microenvironment is capable of suppressing the action of the immune system through several mechanisms such as recruitment of cell modulators. Development of new therapies that avoid this immune evasion could improve the response to the current treatments for this pathology. Natural Killer (NK) cells are cellular components of the immune system more difficult to deceive by tumor cells and with greater cytotoxic activity. Their use in immunotherapy gains strength because they are a less toxic alternative to existing therapy, but the current research focuses on mimicking the NK attack strategy. Here, we summarize the most recent studies regarding molecular mechanisms involved in the GB and immune cells interaction and highlight the relevance of NK cells in the new therapeutic challenges. |
| first_indexed | 2024-03-12T06:41:40Z |
| format | Article |
| id | doaj.art-f22a9b25961c4bfc96bbcfe41ce6744b |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-12T06:41:40Z |
| publishDate | 2018-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-f22a9b25961c4bfc96bbcfe41ce6744b2023-09-03T00:58:05ZengMDPI AGCancers2072-66942018-12-01101252210.3390/cancers10120522cancers10120522NK Cell-Based Glioblastoma ImmunotherapyIrene Golán0Laura Rodríguez de la Fuente1Jose A. Costoya2Molecular Oncology Laboratory MOL, Departamento de Fisioloxia, CiMUS, Facultade de Medicina, Universidade de Santiago de Compostela, IDIS, 15782 Santiago de Compostela, SpainMolecular Oncology Laboratory MOL, Departamento de Fisioloxia, CiMUS, Facultade de Medicina, Universidade de Santiago de Compostela, IDIS, 15782 Santiago de Compostela, SpainMolecular Oncology Laboratory MOL, Departamento de Fisioloxia, CiMUS, Facultade de Medicina, Universidade de Santiago de Compostela, IDIS, 15782 Santiago de Compostela, SpainGlioblastoma (GB) is the most aggressive and most common malignant primary brain tumor diagnosed in adults. GB shows a poor prognosis and, unfortunately, current therapies are unable to improve its clinical outcome, imposing the need for innovative therapeutic approaches. The main reason for the poor prognosis is the great cell heterogeneity of the tumor mass and its high capacity for invading healthy tissues. Moreover, the glioblastoma microenvironment is capable of suppressing the action of the immune system through several mechanisms such as recruitment of cell modulators. Development of new therapies that avoid this immune evasion could improve the response to the current treatments for this pathology. Natural Killer (NK) cells are cellular components of the immune system more difficult to deceive by tumor cells and with greater cytotoxic activity. Their use in immunotherapy gains strength because they are a less toxic alternative to existing therapy, but the current research focuses on mimicking the NK attack strategy. Here, we summarize the most recent studies regarding molecular mechanisms involved in the GB and immune cells interaction and highlight the relevance of NK cells in the new therapeutic challenges.https://www.mdpi.com/2072-6694/10/12/522brain tumormalignant gliomasglioblastomaNK cellsimmunotherapy |
| spellingShingle | Irene Golán Laura Rodríguez de la Fuente Jose A. Costoya NK Cell-Based Glioblastoma Immunotherapy Cancers brain tumor malignant gliomas glioblastoma NK cells immunotherapy |
| title | NK Cell-Based Glioblastoma Immunotherapy |
| title_full | NK Cell-Based Glioblastoma Immunotherapy |
| title_fullStr | NK Cell-Based Glioblastoma Immunotherapy |
| title_full_unstemmed | NK Cell-Based Glioblastoma Immunotherapy |
| title_short | NK Cell-Based Glioblastoma Immunotherapy |
| title_sort | nk cell based glioblastoma immunotherapy |
| topic | brain tumor malignant gliomas glioblastoma NK cells immunotherapy |
| url | https://www.mdpi.com/2072-6694/10/12/522 |
| work_keys_str_mv | AT irenegolan nkcellbasedglioblastomaimmunotherapy AT laurarodriguezdelafuente nkcellbasedglioblastomaimmunotherapy AT joseacostoya nkcellbasedglioblastomaimmunotherapy |